HCW Biologics
Miramar, United States · Biopharma, Biotechnology, Health Care · 50 employees
HCW Biologics is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between chronic, low-grade inflammation, and age-related diseases, such as cancer, cardiovascular diseases, diabetes, neurodegenerative diseases, autoimmune diseases, as well as other conditions such as long-haul COVID-19.
Funding history
- Series seed — $4.0M — Jun 2026
- Funding Round — $6.9M — Dec 2024
- Series seed — $2.5M — Feb 2024
- Funding Round — $26.3M — Apr 2023
- Funding Round — $6.2M — Oct 2020
Recent signals
- Jun 08, 2026: Raised $4.0M in Series seed
- May 29, 2026: SEC 8-K (5.02): On May 29, 2026, HCW Biologics Inc. disclosed that it received notice from Nasdaq regarding non-compliance with the minimum bid price requirement for continued listing. The notice was sent due to the company's stock maintaining a bid price below $1 for 30 consecutive business days. The company had previously executed a 1-for-40 reverse stock split on April 11, 2025, which impacted their compliance timeframe. Following this notice, the Nasdaq Hearings Panel granted HCW Biologics an extension to regain compliance, indicating the regulatory timeline for resolving this issue. This situation may have strategic implications for the company’s market presence and investor confidence.
- Nov 19, 2025: HCW Biologics Enters Amended License Agreement with Trimmune
- Nov 17, 2025: SEC 8-K (1.01): On November 17, 2025, HCW Biologics Inc. entered into an Amended and Restated License, Research and Co-Development Agreement with Beijing Trimmune Biotech Co., Ltd. This agreement follows the assignment of the original agreement from WY Biotech Co., Ltd. to Trimmune. The restructured terms include an exclusive license for HCW11-006 and a payment structure of $3.5 million in cash at closing and the remaining $3.5 million in transferable equity in Trimmune. Additionally, an option for licensing HCW9302 for in vivo applications in China or Asia has been included, with a 90-day closing period for the deal from the agreement execution date.
- Dec 05, 2024: Raised $6.9M
- Nov 18, 2024: HCW Biologics and WY Biotech Enter Worldwide Exclusive License Agreement
- Feb 27, 2024: Raised $2.5M in Series seed
- Apr 27, 2023: Raised $26.3M
See plans & pricing → Track HCW Biologics’s funding, hiring, and signals — with verified contacts — on Fundz.